相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。JAK2 inhibitor therapy in myeloproliferative disorders: rationale, preclinical studies and ongoing clinical trials
A. Pardanani
LEUKEMIA (2008)
Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelotibrosis: recommendations from an ad hoc international expert panel
Ayalew Tefferi et al.
BLOOD (2007)
TG101209, a small molecule JAK2-selective kinase inhibitor potently inhibits myeloproliferative disorder-associated JAK2V617F and MPLW515L/K mutations
A. Pardanani et al.
LEUKEMIA (2007)
Leucocytosis in polycythaemia vera predicts both inferior survival and leukaemic transformation
Naseema Gangat et al.
BRITISH JOURNAL OF HAEMATOLOGY (2007)
Essential thrombocythemia in young individuals:: frequency and risk factors for vascular events and evolution to myelofibrosis in 126 patients
A. Alvarez-Larran et al.
LEUKEMIA (2007)
Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera
Raffaele Landolfi et al.
BLOOD (2007)
Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: interaction with treatment, standard risk factors, and Jak2 mutation status
Alessandra Carobbio et al.
BLOOD (2007)
Risk stratification for survival and leukemic transformation in essential thrombocythemia: a single institutional study of 605 patients
N. Gangat et al.
LEUKEMIA (2007)
Clinical features of polycythemia vera and essential thrombocythemia in Japan: Retrospective analysis of a nationwide survey by the Japanese Elderly Leukemia and Lymphoma Study Group
Kazuo Dan et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2006)
Long-term incidence of hematological evolution in three french prospective studies of hydroxyurea and pipobroman in polycythemia vera and essential thrombocythemia
Jean-Jacques Kiladjian et al.
SEMINARS IN THROMBOSIS AND HEMOSTASIS (2006)
Long-term outcome of 231 patients with essential thrombocythemia - Prognostic factors for thrombosis, bleeding, myelofibrosis, and leukemia
CS Chim et al.
ARCHIVES OF INTERNAL MEDICINE (2005)
Hematopathologic findings in chronic idiopathic myelofibrosis
J Thiele et al.
SEMINARS IN ONCOLOGY (2005)
Vascular and neoplastic risk in a large cohort of patients with polycythemia vera
R Marchioli et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study
G Finazzi et al.
BLOOD (2005)
Efficacy and safety of low-dose aspirin in polycythemia vera
R Landolfi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia
F Passamonti et al.
AMERICAN JOURNAL OF MEDICINE (2004)
Myelofibrosis with myeloid metaplasia following essential thrombocythaemia:: actuarial probability, presenting characteristics and evolution in a series of 195 patients
F Cervantes et al.
BRITISH JOURNAL OF HAEMATOLOGY (2002)
Second malignancies in patients with essential thrombocythaemia treated with busulphan and hydroxyurea: long-term follow-up of a randomized clinical trial
G Finazzi et al.
BRITISH JOURNAL OF HAEMATOLOGY (2000)
分享论文
